CryoPort

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CryoPort achieves record revenue, eyes growth in cell therapy logistics

CryoPort's Q4 2022 performance reflects robust revenue growth and strategic investments, positioning the company for further expansion in cell and gene therapy logistics.
While facing challenges in manufacturing capacity and supply chain, CryoPort's focus on revenue diversification and margin improvement initiatives strengthens its competitive position.
The company's outlook for 2023 is optimistic, with opportunities in supporting commercial therapies, market share expansion, and new product launches driving growth.

CryoPort (CYRX) reports strong Q1 revenue growth and eyes global expansion

CryoPort's Q1 performance reflects robust revenue growth and strategic advancements in logistics solutions.
While facing industry challenges and capacity constraints, CryoPort is leveraging opportunities for expansion and innovation.
The company's focus on acquisitions, partnerships, and market growth positions it well for future success.
Investments in capabilities and global expansion underscore CryoPort's commitment to driving revenue and operational excellence.

CryoPort reports Q2 revenue impact from China, remains confident in growth

CryoPort faces challenges from China's economic conditions but remains confident in its long-term growth drivers in the cell and gene therapy industry.
Strategic investments in technology, premium product positioning, and operational enhancements are key strengths driving future growth and competitiveness.
Navigating short-term challenges, seizing expansion opportunities, and leveraging synergies with MVE in China are crucial for CryoPort's future success.

CryoPort reports robust Q3 earnings, eyes growth in life sciences

CryoPort's Q3 results met expectations, showcasing growth in revenue and execution of its corporate strategy for long-term profitability.
The company's performance reflects strong demand, strategic acquisitions, and a focus on innovation and customer service.
While facing challenges like manufacturing capacity and rising costs, CryoPort remains well-positioned to capitalize on market opportunities.
With a clear outlook for future growth and a stable financial position, CryoPort is poised for continued success in the life sciences industry.

CryoPort reports strong revenue, eyes cell therapy growth in 2024

CryoPort's FY 2023 performance driven by service revenue and global clinical trial support.
Focused on revenue growth in cell and gene therapy industry, introducing innovative products.
Addressing challenges in market competition, revenue trends, and debt management.
Positioned for progressive advancement in 2024, capitalizing on market opportunities.

Cryoport maintains revenue guidance amidst challenges, eyes growth opportunities

Cryoport maintains revenue guidance despite Q1 challenges, focusing on growth drivers and cost-saving measures for improved financial performance.
Strong cash balance, collaborations with logistics companies, and ongoing revenue growth initiatives position Cryoport for future success.
Challenges in MVE business and biologistics revenue softness require attention, but opportunities lie in financial improvement and revenue growth drivers.
Anticipation of continuous progression in the second half and positive integration with CRYOPDP highlight growth prospects for Cryoport.

CryoPort reports strong Q2 revenue growth, eyes profitability by 2025

CryoPort's Q2 2024 performance reflects robust revenue growth and cost-saving initiatives.
While facing challenges in soft demand and market conditions, the company eyes growth opportunities.
Confidence in revenue guidance and proactive measures signal a strategic path to profitability.
Strengthening commercial revenue and upcoming facility openings position CryoPort for future growth.

CryoPort reports Q3 growth, focuses on profitability and cost reduction

CryoPort's Q3 performance showcased growth in Life Sciences Services and strategic initiatives to drive profitability.
Despite challenges in the life sciences sector and uneven market recovery in MVE division, CryoPort remains focused on cost reduction and long-term growth.
Opportunities lie in new product launches, high-value contract acquisitions, and maintaining financial strength post-election.
Overall, CryoPort's resilience and strategic focus position the company for sustained growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CryoPort (NASDAQ: CYRX ) stock is falling on Thursday after the cell and gene therapy products company released preliminary results for the second quarter of 2023. The bad news for investors in CYRX stock starts with its expected revenue of $56.5 million to $57.5 million for the quarter.

Why Is CryoPort (CYRX) Stock Down 26% Today?

Shares of Cryoport Inc. CYRX, +3.58% fell 29% in premarket trading on Thursday after the life-science logistics company issued a revenue warning, noting weaker than expected global demand for capital equipment and clinical trial start delays. Cryoport expects second quarter revenue to be in the range of $56.5 million to $57.5 million, down 11% at the midpoint from the same period a year earlier, the company said in a release late Wednesday.

Cryoport shares slide 29% after revenue warning

Second quarter results were impacted by weaker than expected global demand for capital equipment; clinical trial start delays; and slower than expected ramps from certain clients Second quarter revenue expected in the range of $56.5 - $57.5 million Full year 2023 revenue now expected in the range of $233 - $243 million Long-term outlook robust with cell and gene therapy industry expected to grow at a ten-year CAGR in excess of 22% NASHVILLE, Tenn. , July 12, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services for the fast growing cell and gene therapy industry, today announced certain preliminary results for second quarter 2023 and updated its expectations for full year 2023 revenue expectations.

Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations

Cryoport, Inc. is well-positioned to benefit from the growth in the cell and gene therapy industry due to its dominant position in the cold-chain logistics market and potential for substantial revenue growth. The company's global presence and focus on proximity to manufacturing locations, along with strategic acquisitions, have expanded its market presence and boosted demand for its services. I view the stock as a buy and have an end of year price target of $25 on the stock.

Cryoport: A Strong Player In Cold-Chain Logistics With Solid Growth Prospects

SYDNEY and NASHVILLE, Tenn., June 29, 2023 /PRNewswire/ -- IVFAustralia, an Australian-based provider of full-service fertility care, IVF and related services as part of the Virtus Health network, and Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions supporting the life sciences, reproductive medicine and animal health industries, today announced that IVFAustralia has selected Cryoport as its exclusive supply chain solutions partner for its global reproductive material shipments.

IVFAustralia Selects Cryoport as Exclusive Supply Chain Solutions Provider

Cryoport, Inc. (NASDAQ:CYRX ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Todd Fromer - Investor Relations Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and Investor Relations Conference Call Participants Puneet Souda - SVB Securities Matthew Stanton - Jefferies John Sourbeer - UBS David Larsen - BTIG Paul Knight - KeyBanc Capital David Saxon - Needham & Company Jacob Johnson - Stephens Yuan Zhi - B. Riley Financial Operator Welcome to the Cryoport First Quarter 2023 Earnings Conference Call.

Cryoport, Inc. (CYRX) Q1 2023 Earnings Call Transcript

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.31 per share a year ago.

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates

Record revenue of $63 million, representing 20% growth year-over-year Growth across all lines of business: Biopharma/Pharma revenue up 19%; Animal Health revenue up 30%; Reproductive Medicine revenue up 13% year-over-year Commercial Cell and Gene Therapy revenue up 28% year-over-year, now supporting 82 Phase 3 clinical trials Strong balance sheet with $523 million in cash and short-term investments NASHVILLE, Tenn. , May 4, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, today announced financial results for the three months ended March 31, 2023.

Cryoport Reports First Quarter 2023 Results

CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will CryoPort, Inc. (CYRX) Report Negative Q1 Earnings? What You Should Know

NASHVILLE, Tenn. , April 27, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, reproductive medicine and animal health industries, today announced that the Company will report financial results for the first quarter ended March 31, 2023 on Thursday, May 4, 2023 after U.S. markets close.

Cryoport to Report First Quarter 2023 Financial Results on May 4, 2023

NASHVILLE, Tenn. , April 25, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, reproductive medicine and animal health industries, today announced that it has signed a new three-year agreement with Boston IVF , a pioneer in reproductive healthcare and innovative research and one of the world's most experienced fertility treatment providers.

Cryoport Signs New Supply Chain Solutions Agreement with Boston IVF to Support Reproductive Material Shipments Across the U.S.

BRENTWOOD, TN / ACCESSWIRE / April 11, 2023 / The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period. A burgeoning sector within biotech is the cell and gene therapy (C>) market.

Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?

Cryoport to Support The Prelude Network® and MyEggBank®'s Reproductive Material Shipments with its end-to-end supply chain solutions NASHVILLE, Tenn. , March 28, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry and a leader in supply chain solutions for the reproductive medicine markets, today announced a multi-year agreement with Inception Fertility™ (Inception), North America's largest provider of comprehensive fertility services.

Cryoport Announces Multi-Year Agreement with Inception Fertility

NASHVILLE, Tenn. , March 13, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry, with focus on the bio-pharmaceutical and cell and gene therapy markets, today confirms that the Company does not have any exposure or business relationship with Silicon Valley Bank.

Cryoport Confirms No Financial Exposure to Silicon Valley Bank

Cryoport, Inc. (NASDAQ:CYRX ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Conference Call Participants Michael Almisry - SVB Securities Matt Stanton - Jefferies John Sourbeer - UBS David Larsen - BTIG David Saxon - Needham & Company Jacob Johnson - Stephens Yuan Zhi - B. Riley Securities Operator Good afternoon, and welcome to Cryoport's Fourth Quarter and Full Year 2022 Earnings Conference Call.

Cryoport, Inc. (CYRX) Q4 2022 Earnings Call Transcript

CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -14.29% and 4.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates

2022 revenue reached a record $237 million, commercial revenue up 27% year-over-year Now supporting a record 654 global clinical trials and 10 commercial therapies Entering 2023 with $523 million in cash and short-term investments Revenue guidance for the full year 2023 of $270 - $290 million, up 18% year-over-year at the mid-point NASHVILLE, Tenn. , Feb. 23, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry, with focus on the bio-pharmaceutical and cell and gene therapy markets, today announced financial results for the three months and year ended December 31, 2022.

Cryoport Reports Fourth Quarter and Full Year 2022 Results

NASHVILLE, Tenn. , Feb. 15, 2023 /PRNewswire/ --  Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2022 on Thursday, February 23, 2023 after U.S. markets close.

Cryoport to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Cryoport has been punished over the last 12 months amid a number of downside catalysts. Shares have recently curled up off 52-week lows, asking the question on whether this is an appropriate time for entry.

Cryoport: Differentiated Offering In The Life Sciences Value Chain

Syneos Health

Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services NASHVILLE, Tenn. , Jan. 18, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry focused on the pharmaceutical and cell and gene therapy markets, today announced a new strategic partnership with Syneos Health® (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success.

Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies

NASHVILLE, Tenn. , Dec. 20, 2022 /PRNewswire/ -- Cryoport, Inc.  (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer, will be presenting at the J.P.

Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference

Despite macroeconomic concerns, Cryoport is still generating a 7% revenue growth for the quarter. The new Houston facility that is in collaboration with Takeda would start generating sales as soon as next year.

Cryoport: The Golden Stock

Cryoport, Inc. (NASDAQ:CYRX ) Q3 2022 Results Conference Call November 3, 2022 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Dr. Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and Investor Relations Conference Call Participants Puneet Souda - SVB Securities John Sourbeer - UBS Brandon Couillard - Jefferies David Larsen - BTIG David Saxon - Needham & Company Yuan Zhi - B. Riley Securities Jacob Johnson - Stephens Operator Good afternoon, and welcome to Cryoport's Third Quarter 2022 Earnings Conference Call.

Cryoport, Inc. (CYRX) Q3 2022 Earnings Call Transcript

Third quarter revenue of $60.5 million; nine months 2022 revenue reaches $176.9 million; Cryoport Systems' revenue up 25% year-over-year $530 million in cash and short-term investments Supporting a record 643 global clinical trials; 61 net new trials added (year-over-year) Entered strategic relationship with Takeda's BioLife Plasma Services for apheresis collection and leukopak production Record number of new products and offerings slated to be released by Cryoport in 2023 NASHVILLE, Tenn. ,  Nov. 3, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and nine-month periods ended September 30, 2022.

Cryoport Reports Results for the Third Quarter 2022

NASHVILLE, Tenn. , Oct. 27, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended September 30, 2022 (third quarter 2022) on Thursday, November 3, 2022 after U.S. markets close.

News for CryoPort Stock (CYRX)